ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)

Apheris and Ginkgo Datapoints launched the Antibody Developability Consortium with AbbVie, argenx, Lundbeck and Takeda. Members contribute proprietary antibody sequences to train AI models on 10,000 antibodies without exposing raw data. The dataset is due early 2027 and aims to predict which antibody drugs can be manufactured and reach the clinic.
Tap to vote and see what everyone thinks.
Summary by ByteBrief